Medline Inc. launches secondary offering of Class A common stock

Medline Inc. has recently announced the launch of a secondary offering of Class A common stock by certain selling stockholders affiliated with Blackstone Inc., The Carlyle Group Inc., Hellman & Friedman LLC, and a subsidiary of the Abu Dhabi Investment Authority. The underwritten public offering includes 75,000,000 shares of Medline’s Class A common stock, with the Selling Stockholders granting the underwriters an option to purchase an additional 11,250,000 shares.

It is important to note that Medline itself is not selling any shares of Class A common stock in this offering and will not receive any proceeds from the sale. Acting as global coordinators and joint bookrunning managers for this proposed offering are Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities, and J.P. Morgan, with Blackstone Capital Markets and Carlyle acting as co-managers.

The public offering of these securities will be conducted through a prospectus, and interested parties may obtain copies of the preliminary prospectus from various institutions. A registration statement has been filed with the Securities and Exchange Commission, though it has not yet become effective. It is important to note that these securities cannot be sold or offers accepted until the registration statement becomes effective.

Medline is the largest provider of medical-surgical products and supply chain solutions globally, catering to all points of care. With a diverse product portfolio, strong supply chain, and innovative clinical solutions, Medline plays a crucial role in helping healthcare providers enhance their clinical, financial, and operational outcomes. Headquartered in Northfield, Ill., Medline operates in over 100 countries and employs more than 45,000 people worldwide.

In light of the recent announcement, the press release contains forward-looking statements that look into the future trajectory of the company. These forward-looking statements are based on current expectations but are subject to various risks, uncertainties, and changes in circumstances. Factors beyond Medline’s control can cause actual results to differ materially from these expectations, making it important to consider the risks associated with such investments.

While the company believes that the assumptions underlying these forward-looking statements are reasonable, there is no guarantee of future results or performance. It is essential to understand the factors that could potentially impact Medline’s operations and financial outlook, as detailed in the company’s filings with the SEC. Medline remains committed to transparency and will continue to update investors and stakeholders on any developments that may affect its business operations.

For more information regarding this offering or Medline’s business operations, please refer to the contact information provided for investor relations and media relations. The company’s commitment to providing high-quality healthcare solutions remains unwavering, and this latest offering is a testament to its dedication to excellence in the industry.